Kate Inman - VBI Vaccines Director

VBIV Stock  USD 0.60  0.02  3.45%   

Director

Kate Inman is Director of VBI Vaccines since 2015.
Tenure 9 years
Address 160 Second Street, Cambridge, MA, United States, 02142
Phone617 830 3031
Webhttps://www.vbivaccines.com

VBI Vaccines Management Efficiency

The company has return on total asset (ROA) of (0.295) % which means that it has lost $0.295 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1979) %, meaning that it created substantial loss on money invested by shareholders. VBI Vaccines' management efficiency ratios could be used to measure how well VBI Vaccines manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to -0.76 in 2024. Return On Assets is likely to drop to -0.86 in 2024. At this time, VBI Vaccines' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 93.5 M in 2024, whereas Intangible Assets are likely to drop slightly above 48.2 M in 2024.
The company currently holds 52.23 M in liabilities with Debt to Equity (D/E) ratio of 0.32, which is about average as compared to similar companies. VBI Vaccines has a current ratio of 2.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist VBI Vaccines until it has trouble settling it off, either with new capital or with free cash flow. So, VBI Vaccines' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VBI Vaccines sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VBI to invest in growth at high rates of return. When we think about VBI Vaccines' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Charles BalticMEI Pharma
54
Yuan LiuYS Biopharma Co
37
Shawn TomaselloMesoblast
59
Michael SpoonerMesoblast
N/A
Tamar HowsonMEI Pharma
69
Vickie DriverMediwound
N/A
Thomas ReynoldsMEI Pharma
56
Frederick DriscollMEI Pharma
67
Chunyuan WuYS Biopharma Co
45
William BurnsMesoblast
71
Donal ODwyerMesoblast
63
Christine WhiteMEI Pharma
64
Kevan ClemensMEI Pharma
71
William RueckertMEI Pharma
64
Eric RoseMesoblast
67
Joseph SwedishMesoblast
66
Leah CannMEI Pharma
53
Stephen WillsMediwound
58
Nicholas GloverMEI Pharma
47
BenZion WeinerMesoblast
72
Chunyuan CPAYS Biopharma Co
46
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts. Vbi Vaccines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people. VBI Vaccines (VBIV) is traded on NASDAQ Exchange in USA. It is located in 160 Second Street, Cambridge, MA, United States, 02142 and employs 190 people. VBI Vaccines is listed under Biotechnology category by Fama And French industry classification.

Management Performance

VBI Vaccines Leadership Team

Elected by the shareholders, the VBI Vaccines' board of directors comprises two types of representatives: VBI Vaccines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VBI. The board's role is to monitor VBI Vaccines' management team and ensure that shareholders' interests are well served. VBI Vaccines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VBI Vaccines' outside directors are responsible for providing unbiased perspectives on the board's policies.
Adam Buckley, Vice President - Operations and Project Management
Nicole Anderson, Director Relations
David Anderson, Chief Scientific Officer
Trent Davis, Director
Shayla Forster, Corporate Secretary
Joanne Cordeiro, Director
Sam Chawla, Director
Alan Timmins, Independent Director
Avi Mazaltov, Global SciVac
Misha Nossov, Senior Europe
Marc Kirchmeier, VP of Formulations
Curtis Lockshin, CEO, Director
David Rector, Additional Independent Director
Dmitry Genkin, Director
Michel Wilde, Independent Director
Kate Inman, Director
Ran Nussbaum, Director
FRCPC MD, Chief Officer
Tomer Kariv, Director
Adam Logal, Director
Steven Gillis, Independent Chairman of the Board
Steven Rubin, Chairman of the Board
Jeff Baxter, CEO, Director
Nell Beattie, Chief Officer
Athena Kartsaklis, Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller
James Martin, CFO
FCMA FCMA, CEO Pres
Christopher McNulty, CFO and Head of Business Development
Jeffery FCMA, CEO President
Scott Requadt, Independent Director
Egidio Nascimento, CFO
John Dillman, Chief Officer

VBI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VBI Vaccines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards VBI Vaccines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, VBI Vaccines' short interest history, or implied volatility extrapolated from VBI Vaccines options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for VBI Stock analysis

When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.79)
Revenue Per Share
0.689
Quarterly Revenue Growth
19.896
Return On Assets
(0.29)
Return On Equity
(2.20)
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.